04.16 - Antihypertensives (Bahouth) Flashcards
2 additional actions of Losartan
Competitive antagonist of TXA2 receptor; Increase Uric Acid excretion
2 third gen beta blockers
Bisoprolol, Nebivolol
A poor response to Thiazides may reflect
Either overwhelming load of dietary Na, or impaired renal capacity to excrete the Na
A1-blockers end in
azocin
ACEi’s and ARBs are superior in HTN pt’s with
High renin levels (young people, middle-aged caucasians)
ACEi’s end in
pril
ACEi’s/ARBs should be avoided in any condition that causes
Hyperkalemia
Action of Aliskerin
Renin inhibitor
Action of Nebivolol
Highly B1 selective, with NO-mediated vasodilation
Advantage of secretion of renal prostaglandins
Catopril –> Delays progression of renal disease in diabetics
AE’s of ACEi’s besides dry cough
Hypotension; Hyperkalemia; Angioedema; Fetotoxicity
Anti-oxididant BB
Carvedilol, Nebivolol
ARB’s end in
sartan
BB that prevents LDL oxidation and decreases LDL uptake into coronaries
Carvedilol
BB with Significant ISA
Pindolol (also Timolol)
BB with significant membrane stabilizing activity
Propanolol (also Metoprolol, Pindolol)
BB without Lipid Solubility
Atenolol
BB’s are highly preferred in HTN patients with
MI, IHD, CHF
BB’s are moderately preferred in HTN patients with
Hyperthyroidism, Migraines
Best tolerated drugs for monotx of HTN
Diuertics and ACEi’s
Can a1 blockers be given as monotherapy
No
Can CCB’s be used in diabetics
Yes
CCB’s should be reserved for what patients
do not tolerate diuretics, BB’s, ACEi’s
Clinical uses of Hydralazine
IV in HTN emergency from eclampsia
Clinical uses of Nitroprusside
IV for HTN emergencies in patients with ventricular failure
Clonidine withdrawal
HTN
Common side effect of Sedation
Alpha2 agonists
Competitive antagonist of TXA2 receptor; Increase Uric Acid excretion
2 additional actions of Losartan
Dihydropyridines end in
dipine
Do ACEi’s have positive impact on mortality in CHF
yes
Do ARB’s affect CYP metabolism
No
Do BB’s cause retention of salt and water?
No, can be administered without diuretic
Effect of ARBs on TPR, PV, CO, BP
Decrease all
Effects of alpha2 agonists
Dec PVR, Dec HR
Effects of ARB’s
Vasodilation and Na excretion –> Dec TPR, BV, CO, BP
First and second drugs administered to diabetic patient with HTN
ACEi/ARBs first, then CCB
Hemodynamic effects of alpha1 blockers
Decrease TPR and Reduce BP
Hemodynamic effects of Nebivolol
Significant increase SV, maintains CO and systemic blood flow
Hemodynamic effects of Nitroprusside
Dec TPR; Dec CO in normal, but inc CO in patients with ventricular failure (afterload reduced)
Highly B1 selective, with NO-mediated vasodilation
Action of Nebivolol